ATP1A3 mutations have also been linked to additional “intermediate” phenotypes and clinical signs in isolation or combination including ataxia, dystonia, relapsing encephalopathy, developmental delay with static cognitive impairment, hypotonia, epileptic seizures, ventricular dysrhythmias, and paroxysmal dyskinesias. This evidence concerns the gene ATP1A3 and Global developmental delay.